Horien Biotech (7814) officially listed on the OTC market today (July 16th), having transitioned from the Emerging Stock Market to the OTC Market. The company stated that benefiting from growing demand in the US, Taiwan, and overseas markets, its June revenue more than doubled year-on-year. Meanwhile, its overseas market expansion and new product development continue to advance. Recently, it obtained market access permits for high-risk medical devices in Thailand and is actively expanding into Southeast Asia and Europe. Coupled with the development of new products such as biodegradable catheter stents and collagen regeneration patches, this adds growth momentum to future operations. Horien Biotech's June revenue was NT$15 million, a 229.23% increase month-on-month and a 209.29% increase year-on-year. Second-quarter revenue was NT$25 million, a 3.95% increase quarter-on-quarter and a 50.58% increase year-on-year. First-half revenue was NT$48 million, a 55.78% increase year-on-year.

 Horien Biotech stated that its overseas expansion continues to progress. In early July, it obtained three Class 4 high-risk medical device market access permits in Thailand, successfully entering the ASEAN high-end medical device market. Related Class 3 medical device licenses in the Philippines and Vietnam are also expected to be obtained soon. In addition, the company's bio-ink products are planned for official export to the European market by the end of this year, extending its operations from Asia to the European and American markets.

 Regarding new products, Horien Biotech's independently developed biodegradable ureteral stent has obtained a Taiwanese invention patent, with patents in the US, Europe, and China to follow. The product has completed sample development and entered the animal testing phase. The company points out that no similar product globally has yet obtained medical device certification. This product eliminates the clinical pain point of requiring a second surgery to remove traditional ureteral stents, targeting the multi-billion dollar medical device market. Another new product, collagen regeneration patches, is developed using the company's advanced decellularization technology and is mainly used for surgical and orthopedic tissue repair. It has entered the production line trial stage and is expected to become an important growth driver for the medium- to long-term product line.

 To secure the supply of raw materials for high-end medical devices, Horien Biotechnology's subsidiary, Shengli Biotechnology, has signed memorandums of understanding and cooperation agreements with Taiwan Sugar Corporation and Taiwan Livestock Corporation to establish a medical-grade raw material supply chain that complies with ISO 13485 medical device quality management system and ISO 22442 animal tissue medical device risk management standards, strengthening its integrated supply chain from raw materials to finished products.

 Looking ahead, Horien Biotechnology Chairman Tsai Kuo-Tien (pictured, first from left) stated that the company's listing on the OTC market is a significant milestone. Moving forward, the company will continue to deepen its existing markets in dentistry and surgery, while accelerating its development of high-end medical devices and innovative products. As medical device certifications are obtained in various countries and new products gradually enter the harvest stage, the company expects to increase its global market penetration, continuously driving its operational growth.

Report Link: